Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02981472 · ClinicalTrials.gov registry record · Phase 2
A Study of the Safety and Pharmacokinetics of Apixaban Versus Vitamin K Antagonist (VKA) or Low Molecular Weight Heparin (LMWH) in Pediatric Subjects With Congenital or Acquired Heart Disease Requiring Anticoagulation
A Phase 2 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 2
- Development phase
- 192
- Enrollment target
NCT02981472 is a Phase 2 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 192 participants.
The verdict
NCT02981472, a Phase 2 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 192 participants
- Enrollment target
Study Summary
To investigate the safety and pharmacokinetics of apixaban in children with congenital or acquired heart disease who have a need for anticoagulation.
Interventions
- DRUG Apixaban
- DRUG Low Molecular Weight Heparin (LMWH)
- DRUG Vitamin K Antagonist (VKA)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 192 participants |
| Start Date | 2017-01-19 |
| Est. Completion | 2021-10-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02981472
The ClinicalTrials.gov registry entry for NCT02981472 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 192 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Apixaban is the first listed.
NCT02981472 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02981472 about?
NCT02981472 is a clinical study titled "A Study of the Safety and Pharmacokinetics of Apixaban Versus Vitamin K Antagonist (VKA) or Low Molecular Weight Heparin (LMWH) in Pediatric Subjects With Congenital or Acquired Heart Disease Requiring Anticoagulation". To investigate the safety and pharmacokinetics of apixaban in children with congenital or acquired heart disease who have a need for anticoagulation.
What is the current status of trial NCT02981472?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 192 participants. The study started on 2017-01-19. Estimated completion is 2021-10-18.
What interventions are being tested in trial NCT02981472?
The interventions under investigation include: Apixaban (DRUG), Low Molecular Weight Heparin (LMWH) (DRUG), Vitamin K Antagonist (VKA) (DRUG).
Who is sponsoring clinical trial NCT02981472?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.